ARAY
Price
$1.81
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
69 days until earnings call
MLSS
Price
$0.67
Change
-$0.00 (-0.00%)
Updated
Nov 13 closing price
One day until earnings call
Ad is loading...

ARAY vs MLSS

Header iconARAY vs MLSS Comparison
Open Charts ARAY vs MLSSBanner chart's image
Accuray
Price$1.81
Change-$0.00 (-0.00%)
Volume$703.81K
CapitalizationN/A
Milestone Scientific
Price$0.67
Change-$0.00 (-0.00%)
Volume$83.06K
CapitalizationN/A
ARAY vs MLSS Comparison Chart
Loading...
ARAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ARAY vs. MLSS commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARAY is a Hold and MLSS is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (ARAY: $1.81 vs. MLSS: $0.67)
Brand notoriety: ARAY and MLSS are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ARAY: 111% vs. MLSS: 85%
Market capitalization -- ARAY: $244.95M vs. MLSS: $47.46M
ARAY [@Medical Specialties] is valued at $244.95M. MLSS’s [@Medical Specialties] market capitalization is $47.46M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.01B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARAY’s FA Score shows that 0 FA rating(s) are green whileMLSS’s FA Score has 0 green FA rating(s).

  • ARAY’s FA Score: 0 green, 5 red.
  • MLSS’s FA Score: 0 green, 5 red.
According to our system of comparison, ARAY is a better buy in the long-term than MLSS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARAY’s TA Score shows that 3 TA indicator(s) are bullish while MLSS’s TA Score has 4 bullish TA indicator(s).

  • ARAY’s TA Score: 3 bullish, 6 bearish.
  • MLSS’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, MLSS is a better buy in the short-term than ARAY.

Price Growth

ARAY (@Medical Specialties) experienced а -10.84% price change this week, while MLSS (@Medical Specialties) price change was -17.61% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -2.23%. For the same industry, the average monthly price growth was +0.54%, and the average quarterly price growth was -4.87%.

Reported Earning Dates

ARAY is expected to report earnings on Jan 22, 2025.

MLSS is expected to report earnings on Apr 07, 2025.

Industries' Descriptions

@Medical Specialties (-2.23% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARAY($245M) has a higher market cap than MLSS($47.5M). MLSS YTD gains are higher at: -2.884 vs. ARAY (-36.042). ARAY has higher annual earnings (EBITDA): 5.93M vs. MLSS (-6.99M). ARAY has more cash in the bank: 72.8M vs. MLSS (4.62M). MLSS has less debt than ARAY: MLSS (422K) vs ARAY (202M). ARAY has higher revenues than MLSS: ARAY (447M) vs MLSS (9.81M).
ARAYMLSSARAY / MLSS
Capitalization245M47.5M516%
EBITDA5.93M-6.99M-85%
Gain YTD-36.042-2.8841,250%
P/E RatioN/AN/A-
Revenue447M9.81M4,558%
Total Cash72.8M4.62M1,575%
Total Debt202M422K47,867%
FUNDAMENTALS RATINGS
ARAY vs MLSS: Fundamental Ratings
ARAY
MLSS
OUTLOOK RATING
1..100
203
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9596
PRICE GROWTH RATING
1..100
4764
P/E GROWTH RATING
1..100
61100
SEASONALITY SCORE
1..100
35n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARAY's Valuation (82) in the Medical Specialties industry is in the same range as MLSS (96). This means that ARAY’s stock grew similarly to MLSS’s over the last 12 months.

ARAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MLSS (100). This means that ARAY’s stock grew similarly to MLSS’s over the last 12 months.

ARAY's SMR Rating (95) in the Medical Specialties industry is in the same range as MLSS (96). This means that ARAY’s stock grew similarly to MLSS’s over the last 12 months.

ARAY's Price Growth Rating (47) in the Medical Specialties industry is in the same range as MLSS (64). This means that ARAY’s stock grew similarly to MLSS’s over the last 12 months.

ARAY's P/E Growth Rating (61) in the Medical Specialties industry is somewhat better than the same rating for MLSS (100). This means that ARAY’s stock grew somewhat faster than MLSS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARAYMLSS
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARAY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MLSS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYRCX41.600.21
+0.51%
Rydex Retailing C
JHJAX25.70N/A
N/A
JHancock ESG Large Cap Core A
GMHPX14.17N/A
N/A
Goldman Sachs Rising Dividend Gr P
AMAGX84.12-0.22
-0.26%
Amana Growth Investor
GTDIX33.27-0.15
-0.45%
Invesco EQV Emerging Markets All Cap R5

ARAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARAY has been loosely correlated with BRKR. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ARAY jumps, then BRKR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARAY
1D Price
Change %
ARAY100%
-5.24%
BRKR - ARAY
41%
Loosely correlated
-0.12%
BNGO - ARAY
39%
Loosely correlated
+4.53%
IQV - ARAY
38%
Loosely correlated
-0.96%
LH - ARAY
38%
Loosely correlated
+0.80%
ALGN - ARAY
38%
Loosely correlated
-1.85%
More

MLSS and

Correlation & Price change

A.I.dvisor tells us that MLSS and SRDX have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MLSS and SRDX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLSS
1D Price
Change %
MLSS100%
-4.30%
SRDX - MLSS
26%
Poorly correlated
-0.93%
VTAK - MLSS
25%
Poorly correlated
+10.47%
ACRS - MLSS
24%
Poorly correlated
-4.88%
ARAY - MLSS
24%
Poorly correlated
-5.24%
NSPR - MLSS
23%
Poorly correlated
+5.24%
More